Jun 13, 2023 / 04:20PM GMT
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research Analyst
And we're back. Welcome, everybody, to our third session this morning at the Goldman Sachs Healthcare Conference. My name is Chris Shibutani along with the team, especially the team that's based in London, (inaudible). Thank you very much.
We're very pleased that GlaxoSmithKline, GSK, can join us today. Today, we have Tony Wood, who is the Chief Scientific Officer. The focus of our conversation, there's so much that we can always talk about with GSK in terms of portfolio strategy, et cetera. But I always like to make sure that we focus the relatively short time that we have here, a 30-minute discussion, to being able to go a little bit more into depth.
There's a lot of critical areas from the clinical development standpoint and the pipeline that is really sort of your power alley, and then we're also going to beg you to ask, comment on some things that are clearly relevant from that pipeline standpoint in the HIV side. But to begin with, just to familiarize the room a little bit about who we're talking to,
GSK plc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers